Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.76 |
| ▸ | BRD4 | O60885 | 7/20 | 0.76 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.76 |
| ▸ | DCLK1 | O15075 | 5/20 | 0.71 |
| ▸ | MAPK7 | Q13164 | 11/20 | 0.68 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.62 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAK | O14976 | 1/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.48 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.48 |
| ▸ | DCLK2 | Q8N568 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22605975 | 0.97 | LRRK2 (0.76) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL18313550 | 0.93 | MAPK7 (0.67) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL29389108 | 0.86 | LRRK2 (1.00) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL29596956 | 0.86 | LRRK2 (1.00) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL616761 | 0.86 | LRRK2 (1.00) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL616960 | 0.85 | LRRK2 (0.90) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL16982790 | 0.85 | LRRK2 (0.73) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL16982791 | 0.83 | LRRK2 (0.70) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL16979641 | 0.81 | BRD4 (1.00) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL616339 | 0.81 | MAPK7 (1.00) | LRRK2BRD4BRDTDCLK1MAPK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | PETER MACCALLUM CANCER INSTITUTE (AU) | 2019-06-27 | — | — | US | disclosed |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9695172-B2 | Diazepane derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695172-B2 | Diazepane derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| WO-2016201370-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20160347749-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160347749-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| WO-2015117083-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | CHUK, BCOR, MYC | LRRK2 1732/4885BRD4 205/4885BRDT 85/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | LRRK2 1732/4885BRD4 205/4885BRDT 85/4885 |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | LRRK2 1732/4885BRD4 205/4885BRDT 85/4885 |
| US-20160347749-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRD3 | LRRK2 1097/4885BRD4 2/4885BRDT 1/4885 |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | BRD4, BRD3, BRPF3 | LRRK2 1955/4885BRD4 1/4885BRDT 4/4885 |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | LRRK2 1732/4885BRD4 205/4885BRDT 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.